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Major	haemorrhage	is	an	important	cause	of	morbidity	and	mortality,	affecting	up	to	40%	of	1	
all	trauma	patients	(Stanworth	et	al,	2016)	and	10%	of	cardiac	surgery	patients	(Serraino	&	2	
Murphy,	 2017).	 Blood	 loss	 is	 one	 of	 the	 main	 causes	 of	 morbidity	 following	 liver	3	
transplantation	 (Gurusamy	 et	 al,	 2011)	 and	 is	 one	 of	 the	most	 common	 causes	 of	 death	4	
worldwide	in	women	at	the	time	of	delivery	(Say	et	al,	2014).	Diagnosis	of	major	bleeding	is	5	
difficult	 and	 is	 often	 made	 using	 clinical	 measures	 (e.g.	 rising	 heart	 rate,	 falling	 blood	6	
pressure)	but	these	measures	can	be	 insensitive,	particularly	 in	younger	patients	 in	whom	7	
blood	 loss	can	be	masked	and	haemodynamic	stability	preserved	or	 in	elderly	patients	on	8	
cardiovascular	 modulating	 medication.	 Detection	 and	 correction	 of	 coagulopathy	 is	9	
therefore	an	important	aspect	of	management	of	severe	haemorrhage.	10	
	11	
BSH	 guidelines	 (Hunt	 et	 al,	 2015)	 recommend	 the	 use	 of	 serial	 standard	 laboratory	 tests	12	
(SLTs)	 taken	every	30-60	minutes	 to	monitor	major	haemorrhage	 in	most	clinical	 settings.	13	
There	are,	however,	inherent	difficulties	with	SLTs.	Average	turn-around-times	are	between	14	
27	(Cotton	et	al,	2011)	and	77	minutes	(Davenport	et	al,	2011)	which	is	often	too	slow	for	a	15	
rapidly	 evolving	 situation.	 Furthermore,	 the	 ability	 of	 SLTs	 to	 predict	major	 bleeding	 and	16	
therefore	allow	pre-emptive	treatment	is	limited	(Segal	et	al,	2005,	Davenport	et	al,	2011).	17	
In	liver	transplantation	for	example,	it	is	well	known	that	the	prothrombin	time	(PT)	or	the	18	
International	 Normalised	 Ratio	 (INR)	 does	 not	 differentiate	 between	 patients	who	will	 or	19	
will	 not	 bleed	 excessively	 (Massicotte	 et	 al,	 2014),	 nor	 does	 an	 elevated	 	 INR	 exclude	20	
underlying	hypercoagulability	(Krzanicki	et	al,	2013).		21	
	22	
Viscoelastic	haemostatic	assays	 (VHA)	are	 increasingly	being	used	during	the	management	23	
of	major	bleeding.	 There	 are	 several	 recent	 comprehensive	 systematic	 reviews	evaluating	24	
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the	 available	 evidence	 (Whiting	 et	 al,	 2015,	 Serraino	&	Murphy,	 2017,	 Fahrendorff	 et	 al,	1	
2017).	 	 Current	 NICE	 guidance	 recommends	 VHA	 use	 during	 cardiac	 surgery,	 but	 not	 for	2	
obstetric	or	 trauma	haemorrhage	 (Whiting	et	al,	 2015).	 This	BSH	guideline	 recognises	 the	3	
limited	 available	 evidence	 but,	 within	 these	 constraints,	 aims	 to	 provide	 pragmatic	 and	4	
practical	advice	to	practising	clinicians	as	to	how	to	interpret	and	use	VHA	results	during	the	5	
management	 of	 major	 bleeding	 in	 four	 common	 scenarios:	 obstetric	 haemorrhage,	 liver	6	
disease,	cardiac	surgery	and	trauma	haemorrhage.		7	
	8	
Methodology	9	
This	guideline	was	compiled	according	to	the	BSH	process	at	www.b-s-h.org.uk/guidelines.		10	
Details	of	 the	methodology	for	 inclusion	of	studies,	 including	the	PRISMA	diagram,	can	be	11	
found	 in	 the	 online	 supplement.	Grading	 of	 Recommendations	Assessment,	Development	12	
and	Evaluation	(GRADE)	nomenclature	was	used	to	evaluate	levels	of	evidence	and	to	assess	13	
the	 strength	 of	 recommendations.	 The	 GRADE	 criteria	 can	 be	 found	 at	14	
http://www.gradeworkinggroup.org.	15	
	16	
Review	of	the	manuscript	17	
Review	 of	 the	 manuscript	 was	 performed	 by	 the	 British	 Society	 for	 Haematology	 (BSH)	18	
Guidelines	 Committee	 Haemostasis	 and	 Thrombosis	 Task	 Force,	 the	 BSH	 Guidelines	19	
Committee	and	the	Haemostasis	and	Thrombosis	sounding	board	of	the	BSH.	It	was	also	on	20	
the	members	section	of	the	BSH	website	for	comment.	The	AAGBI	endorsed	the	document.	21	
	22	
Machine	methodology,	quality	assurance	and	test	accuracy		23	
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Viscoelastic	 tests	 include	 thromboelastography	 (TEG),	 thromboelastometry	 (ROTEM)	 and	1	
Sonoclot.	The	most	widely	used	machines	are:	TEG5000	(Haemonetics	Corporation,	IL,	USA),	2	
ROTEM	delta	(TEM	International,	GmbH)	and	Sonoclot	(Sienco	Inc,	Arvada,	CO,	USA).	Until	3	
recently,	all	three	devices	used	similar	principles	based	on	a	cup	and	pin	method	to	measure	4	
the	mechanical	properties	of	clot	formation	in	whole	blood	(see	figures	1a,	1b,	1c).	A	variety	5	
of	 activators	 are	 used	 for	 each	 device	 to	 examine	 different	 aspects	 of	 the	 haemostatic	6	
system	(see	tables	1a,	1b,	1c)	and	as	the	blood	clots	a	graphical	representation	is	made.	A	7	
typical	 trace	 for	 TEG	 and	 ROTEM	 is	 shown	 in	 figure	 2	 and	 a	 Sonoclot	 trace	 in	 figure	 3.	8	
Although	 TEG	 and	 ROTEM	 traces	 look	 identical,	 the	 parameters	 are	 not	 directly	9	
interchangeable	and	should	not	be	regarded	as	equivalent	(Coakley	et	al,	2006,	Venema	et	10	
al,	2010,	Rizoli	et	al,	2016,	Hagemo	et	al,	2015).	11	
	12	
One	of	the	major	drawbacks	of	VHA	machines	has	been	the	need	for	users	to	be	trained	in	13	
basic	pipetting:	the	TEG5000	and	Sonoclot	operate	with	manual	pipetting,	the	ROTEM	delta	14	
with	automated	pipetting.	In	response	to	this	challenge,	the	TEG	and	ROTEM	manufacturers	15	
have	developed	cartridge	based	techniques	designed	to	improve	ease	of	use	and	precision	–	16	
the	TEG6s	and	the	ROTEM	sigma.		17	
	18	
TEG6s	 has	 microfluidic	 cartridges	 pre-loaded	 with	 reagents	 and	 uniquely	 uses	 resonance	19	
technology	to	record	clot	formation	(figure	4).	Each	cartridge	has	four	channels,	containing	20	
different	 reagents	 (table	 1a).	 Despite	 a	 different	 methodology,	 observational	 data	 have	21	
shown	good	correlation	between	TEG5000	and	TEG6s	(R	time,	K	time,	alpha	angle)	(Gurbel	22	
et	 al,	 2016)	 in	 157	 healthy	 volunteers	 and	 300	 cardiac	 patients.	 But	 similarly	 to	 all	 VHA	23	
devices,	theTEG6s	remains	sensitive	to	vibration	(Gill,	2017),	an	important	consideration	for	24	
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road-	or	air-based	analysis.		TEG6s	cartridges	to	detect	anti-thrombin	and	anti-Xa	agents	are	1	
in	development	and	a	pilot	study	(Bliden	et	al,	2017)	showed	high	sensitivity	and	specificity	2	
for	direct	oral	anticoagulant	(DOAC)	therapies.			3	
	4	
Only	one	study	has	compared	ROTEM	sigma	and	delta:	evaluating	EXTEM	and	FIBTEM	in	30	5	
pregnant	 volunteers.	 This	 study	 showed	 no	 differences	 between	 FIBTEM	 A5	 values	 but	6	
reported	 significantly	 lower	 EXTEM	 A5	 and	 shorter	 EXTEM	 CT	 values	 with	 the	 sigma	7	
(Crighton	 et	 al,	 2017).	 Further	 comparative	 data	 are	 needed	 exploring	 new	 versus	 older	8	
technologies,	 since	 switching	 devices	 may	 require	 significant	 adjustments	 to	 the	9	
corresponding	VHA-based	transfusion	algorithm.		10	
	11	
Sample	type	and	pre-analytical	issues	12	
Native	whole	 blood	 samples	 need	 immediate	 analysis.	 Anticoagulated	 samples	 should	 be	13	
analysed	 within	 four	 hours	 of	 venesection.	 No	 specific	 rest	 period	 is	 recommended	 by	14	
manufacturers	 prior	 to	 analysing	 citrated	 blood	 samples.	 Users	 of	 ROTEM	 devices	 have	15	
variously	recommended	resting	samples	between	30	(Andreasen	et	al,	2011,	Armstrong	et	16	
al,	2011)	and	120	(Theusinger	et	al,	2010)	minutes,	whilst	others	report	immediate	testing	17	
(Ogawa	et	al,	2012a,	2012b,	Oswald	et	al,	2010).		18	
Pragmatically,	it	is	reasonable	to	perform	immediate	testing	for	all	VHA	tests.	19	
	20	
Precision	and	accuracy	of	testing	21	
Precision	of	VHA	testing	has	not	been	widely	reported,	although	operator	variation	seems	to	22	
have	an	 important	effect.	CVs	of	2.6	 -	11.2%	for	ROTEM	delta	and	7.4	 -	19%	for	TEG5000	23	
parameters	were	reported	in	one	study	with	seven	operators	(Anderson	et	al,	2014).	Inter-24	
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laboratory	comparison	with	external	quality	assurance	 (EQA)	samples	 shows	much	poorer	1	
precision:		7	-	49%	for	TEG5000	and	7	-	83%	for	ROTEM	delta	(Kitchen	et	al,	2010).	Notably	2	
this	EQA	programme	used	lyophilised	citrated	plasma	samples,	which	may	explain	the	wide	3	
variability.	There	are	no	EQA	data	for	the	TEG6s	or	ROTEM	sigma.	4	
	5	
Internal	quality	control	6	
There	is	no	consensus	on	the	desirable	frequency	of	Internal	Quality	Control	(IQC)	–	reports	7	
have	ranged	from	eight	hourly	(Pommering	et	al,	2014)	to	weekly	(Jeger	et	al,	2012).	As	with	8	
all	IQC,	this	methodology	checks	the	quality	control	of	the	user,	and	the	reagents	as	well	as	9	
the	device.	TEG	manufacturers	recommend	daily	electronic	checks	and	monthly	IQC	for	low	10	
volume	 users	 and	 more	 frequent	 analysis	 for	 higher	 users.	 ROTEM	 recommends	 weekly	11	
quality	 control	 checks	 and	 Sonoclot	 recommends	 a	 viscosity	 check	 daily	 and	 a	 monthly	12	
reference	plasma	quality	 control.	These	are	minimum	recommendations	and	users	 should	13	
take	into	account	volume	of	testing	when	deciding	on	frequency	of	IQC.		14	
	15	
External	quality	assurance	16	
The	 UK	 National	 External	 Quality	 Assurance	 Scheme	 (NEQAS)	 for	 Blood	 Coagulation	17	
programme	 provides	 a	 VHA	 EQA	 service	 for	 TEG5000	 and	 ROTEM	 delta	 which	 uses	18	
lyophilized	citrated	plasma	samples	with	plans	in	place	to	offer	EQA	for	TEG6s	and	ROTEM	19	
sigma.	The	External	quality	Control	of	diagnostic	Assays	and	Tests	 (ECAT)	Foundation	also	20	
offers	an	EQA	scheme	using	lyophilised	plasma.		21	
	22	
Reference	Ranges	23	
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VHA	 tests	 are	 poorly	 standardised	 and	 apart	 from	 manufacturers’	 reported	 reference	1	
ranges,	 there	 is	 no	 published	 consensus	 for	 normal	 ranges.	 Hospitals	 should	 therefore	2	
determine	 local	 references	 ranges	 as	 is	 standard	 practice	 for	 the	 majority	 of	 laboratory	3	
tests.	 Determining	 local	 ranges	may	 not	 be	 practical	 in	 the	 paediatric	 setting	 –	 reference	4	
ranges	have	been	reported	for	children	using	the	ROTEM	delta	(Oswald	et	al,	2010)	and	the	5	
TEG5000	(Chan	et	al,	2007).		6	
	7	
Practice	points:	8	
• Reference	 ranges	 should	 be	 determined	 locally	 and	 re-established	 when	 a	 new	9	
machine	is	introduced.	10	
• For	 non	 cartridge-based	 methods,	 staff	 should	 be	 trained	 and	 have	 good	 pipetting	11	
technique.	Training	and	competency	should	be	documented.	12	
•	 Anticoagulated	 samples	 should	 be	 tested	 within	 four	 hours;	 no	 resting	 period	 is	13	
required.		14	
•	 IQC	should	be	performed	daily	for	high	volume	usage	or	weekly	if	low	volume	usage.	15	
• TEG	and	ROTEM	measures	must	not	be	used	interchangeably.	16	
•	 Participation	in	an	accredited	EQA	programme	is	recommended.	17	
	18	
VHA	traces		19	
Standard	TEG/ROTEM	traces	can	be	divided	into	four	main	sections:			20	
1) Clot	initiation	(R	(reaction)	time	-	TEG5000;	ACT	(activated	clotting	time)	–	rapid	TEG	21	
or	rTEG;	CT	(clotting	time)	–	ROTEM	devices):	is	broadly	similar	to	the	PT	or	activated	22	
partial	thromboplastin	time	(aPTT)	and	measures	from	test	start	until	fibrin	begins	to	23	
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be	 formed.	 Warfarin	 and	 heparin	 prolong	 this	 measurement,	 as	 can	 any	 other	1	
significant	hypocoagulability,	including	low	fibrinogen	concentration.		2	
2) Fibrin	 polymerisation	 (K	 (kinetics)	 time,	α	 angle	 –	 TEG	devices;	 CFT	 (clot	 formation	3	
time),	 α	 angle	 –	 ROTEM	devices):	 reflects	 the	 speed	 at	which	 fibrin	 is	 formed	 and	4	
how	well	 it	 binds	 to	platelets.	 The	value	 is	dependent	on	 sufficient	 fibrinogen	and	5	
platelet	number	and	function.	6	
3) Clot	 strength	 (MA	 (maximum	 amplitude)	 –	 TEG	 devices;	 A	 (amplitude)	 and	 MCF	7	
(maximal	 clot	 firmness)	 –	 ROTEM	 devices):	 these	 measures	 make	 up	 most	 of	 the	8	
trace	 and	 are	 a	 combined	 assessment	 of	 fibrinogen	 and	 platelet	 interaction.	 To	9	
differentiate	 their	 effects	 the	 standard	 VHA	 trace	 should	 be	 compared	 with	 a	10	
fibrinogen	 trace	 (ROTEM	 -	 FIBTEM;	 TEG	 –	 functional	 fibrinogen	 (ff))	 in	 which	 the	11	
contribution	 of	 platelets	 is	 removed	 by	 adding	 a	 platelet	 inhibitor.	 Factor	 XIII	 also	12	
contributes	to	a	small	degree	to	clot	strength.	13	
4) Lysis	 of	 the	 clot	 (LY30	 (lysis	 at	 30	 minutes)	 –	 TEG	 devices;	 ML	 (maximal	 lysis)	 –	14	
ROTEM	 devices):	 some	 clot	 strength	 diminution	 is	 expected	 by	 the	 end	 of	 a	 VHA	15	
trace,	as	platelet	retraction	is	a	normal	phenomenon.	Cut-offs	are	given,	specific	to	16	
each	 device,	 and	 if	 exceeded	 fibrinolysis	 is	 evident.	 Although	 TEG	 and	ROTEM	are	17	
able	 to	 detect	 increased	 lysis,	 they	 are	 insensitive	 to	 mildly	 and	 or	 moderately	18	
increased	 fibrinolysis	 and	 should	 not	 be	 used	 to	 confirm	 its	 absence	 (Raza	 et	 al,	19	
2013)	nor	should	it	be	used	as	a	reason	to	withhold	tranexamic	acid.		20	
VHA	tests	are	generally	insensitive	to	anti-platelet	agents	(except	α2bβ3	blockers)	(Tynngård	21	
et	 al,	 2015).	 Standard	 ROTEM	 tests	 (EXTEM/INTEM	 CT)	 can	 detect	 DOACs	 (dabigatran,	22	
edoxaban,	 rivaroxaban)	at	 therapeutic	 levels,	but	appear	 insensitive	 to	apixaban	 (Seyve	et	23	
al,	2018).	Sonoclot	measures	are	set	out	in	figure	3.	24	
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	1	
Obstetric	and	postpartum	bleeding		2	
VHA	are	most	useful	in	major	obstetric	bleeding	when	the	obstetric	haemorrhage	protocol	3	
is	activated,	though	tests	may	be	run	earlier	if	coagulopathy	is	expected,	e.g.,	with	placental	4	
abruption	or	amniotic	fluid	embolism.			5	
	6	
The	 coagulation	 system	 at	 term	 is	 procoagulant	 and	 normal	 ranges	 for	 many	 TEG	 and	7	
ROTEM	parameters	differ	at	delivery	 from	non-pregnant	values.	On	the	ROTEM	delta,	CTs	8	
are	shorter	and	EXTEM	and	FIBTEM	A5	(amplitude	at	5	minutes),	A10	and	MCF	are	higher	9	
for	women	in	the	third	trimester	of	pregnancy	(Armstrong	et	al,	2011;	van	Rheenen-Flach	et	10	
al,	 2013;	de	 Lange	et	al,	 2014;	Oudghiri	et	al,	 2011).	On	 the	TEG5000,	R	 and	K	 times	 are	11	
shorter	and	alpha	angle	and	MA	higher	at	term	(Della	Rocca	et	al,	2012;	Polak	et	al,	2011).	12	
This	 means	 that	 an	 MA	 or	 MCF	 which	 is	 normal	 for	 the	 non-pregnant	 population	 may	13	
suggest	a	developing	coagulopathy	in	a	term	woman.	An	abnormal	ROTEM	or	TEG	trace	may	14	
help	to	alert	clinicians	to	the	possibility	of	an	amniotic	fluid	embolus	or	placental	abruption.	15	
There	are	no	published	data	on	the	normal	range	for	Sonoclot	during	pregnancy.	16	
	17	
Prediction	of	bleeding/coagulopathy		18	
FIBTEM	and	EXTEM	measured	on	admission	to	delivery	suite	or	before	bleeding	starts	are	19	
not	predictive	of	future	bleeding	(Kaufner	et	al,	2016).	However,	a	low	FIBTEM	A5	and	MCF,	20	
taken	at	the	time	of	moderate	postpartum	haemorrhage	(1000	to	1500	ml),	is	predictive	of	21	
the	need	 for	 transfusion	of	≥4	units	 red	blood	cell	 (RBC)	 [Receiver	operator	 characteristic	22	
area	under	the	curve	(ROC	AUC)	(95%	confidence	intervals	(CI))	0.78	(0.69-0.88)]	and	bleeds	23	
>2500	ml	[0.75	(0.66-0.85)].	Women	who	progressed	to	≥4	units	RBC	had	a	FIBTEM	A5	of	13	24	
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mm	(interquartile	range	(IQR):	10-17)	whereas	those	that	did	not	progress	had	a	FIBTEM	A5	1	
of	19	mm	(17-23)	(Collins	et	al,	2014).	TEG	clot	strength	measures,	using	an	MA	cut	off	of	40	2	
mm	 (kaolin	 TEG5000	MA)	 are	 also	 predictive	 of	 major	 obstetric	 haemorrhage:	 ROC	 AUC	3	
(95%	CI)	 0.9	 (0.83-0.95)	 (Barinov	et	al,	 2016).	 There	 are	no	published	data	on	 the	 role	of	4	
Sonoclot	for	predicting	progression	of	obstetric	bleeding.		5	
	6	
Diagnosis	of	bleeding/coagulopathy		7	
Clauss	 fibrinogen	 and	 FIBTEM	 A5/MCF	 correlate	 moderately	 well	 during	 postpartum	8	
haemorrhage	 (PPH)	 and	 can	be	used	 to	 identify	women	with	 a	 reduced	Clauss	 fibrinogen	9	
(Huissoud	 et	 al,	 2009).	 A	 double	 blind,	 randomised,	 placebo-controlled	 trial	 of	 women	10	
experiencing	 moderate	 to	 severe	 PPH,	 showed	 that	 a	 FIBTEM	 A5	 >12	 mm	 indicates	 a	11	
fibrinogen	 level	 adequate	 for	 haemostasis	 (Collins	 et	 al,	 2017a).	 	 An	 observational	 study	12	
showed	 that	 the	 combination	 of	 an	 EXTEM	 CT	 <100	 sec	 and	 FIBTEM	 A5	 >12	 mm	 was	13	
associated	with	adequate	haemostasis	(Mallaiah	et	al,	2015a,	2015b).	14	
	15	
Tranexamic	 acid	 improves	 outcomes	 during	 PPH	 if	 infused	 within	 3	 hours	 of	 delivery	16	
(WOMAN	 trial,	 2017).	 There	 are	 no	 data	 to	 support	 the	 use	 of	 APTEM	 or	 TEG	 clot	 lysis	17	
parameters	to	guide	tranexamic	acid	infusion.	Normal	APTEM	or	TEG	clot	lysis	results	should	18	
not	be	used	to	withhold	tranexamic	acid.	19	
	20	
There	are	no	published	data	to	link	platelet	number	with	ROTEM	or	TEG	parameters	during	21	
PPH.	 Algorithms	 developed	 for	 other	 causes	 of	 bleeding	 may	 not	 be	 applicable	 in	 this	22	
situation	because	clot	strength	parameters	are	raised	at	the	time	of	delivery.	23	
		24	
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Use	of	ROTEM/TEG/Sonoclot	for	guiding	transfusion	and	haemostatic	therapy	1	
NICE	guidance	does	not	 support	 the	use	of	VHAs	 to	guide	blood	component	 replacement	2	
during	PPH	and	recommends	further	studies	(Whiting	et	al,	2015).		3	
	4	
A	prospective,	double-blind	study	randomised	women	with	moderate	to	severe	PPH	and	a	5	
FIBTEM	 A5	 ≤15	 mm	 to	 fibrinogen	 concentrate	 or	 placebo	 (n=55).	 No	 reduction	 in	6	
transfusion	 requirements	 or	 blood	 loss	was	 reported.	 Subgroup	 analysis	 suggested	 that	 if	7	
FIBTEM	 A5	 ≥12	 mm	 fibrinogen	 infusion	 was	 not	 required	 (Collins	 et	 al,	 2017a).	 In	 the	8	
observation	arm	of	the	same	study,	605	women	were	not	infused	fresh	frozen	plasma	(FFP)	9	
if	 FIBTEM	 A5	 was	 >15	 mm	 or	 bleeding	 had	 stopped.	 This	 did	 not	 result	 in	 any	 women	10	
developing	 clinically	 significant	 haemostatic	 impairment	 defined	 as	 continuing	 bleeding	11	
associated	with	a	PT	or	aPTT	>1.5	times	normal	(Mavrides	et	al,	2016;	Collins	et	al,	2017a;	12	
2017b).	13	
	14	
An	observational	study	showed	that	 infusing	 fibrinogen	concentrate	when	FIBTEM	A5	was	15	
<7	mm,	 or	 <12	mm	with	 severe	 bleeding	 and	 infusing	 FFP	when	 CT	was	 >100	 s	 (n=107),	16	
reduced	 RBC	 usage,	 transfusion-associated	 fluid	 overload	 and	 admission	 to	 the	 intensive	17	
care	unit	(ICU)	compared	to	the	use	of	empirical	transfusion	with	RBC:FFP:platelets	in	a	ratio	18	
of	4:4:1	(n=42)	in	a	before	and	after	study	(Mallaiah	et	al,	2015a,	2015b).		19	
	20	
An	 observational	 study	 compared	 standard	 care	 (n=29)	 with	 early	 surgical	 intervention,	21	
mechanical	 uterine	 pressure	 plus	 TEG-guided	 transfusion	 (n=90).	 There	was	 a	 statistically	22	
significant	reduction	in	hysterectomy,	total	blood	loss	and	FFP	transfusion	in	the	combined	23	
strategy	group.	The	report	does	not	state	what	TEG	parameters	were	used	to	trigger	FFP	or	24	
12	
	
platelet	 transfusion.	 It	not	possible	 to	 conclude	which	of	 the	 interventions	 contributed	 to	1	
the	 improved	 outcomes	 (Barinov	 et	 al,	 2016).	 	 A	 TEG-based	 algorithm	 for	 managing	2	
obstetric	 bleeding	 has	 been	 published	 but	 no	 data	 were	 presented	 on	 whether	 the	3	
algorithm	affected	outcomes	(Hill	et	al,	2012).		4	
	5	
There	are	no	published	data	on	the	role	of	Sonoclot	to	guide	blood	component	use	during	6	
PPH.	7	
	8	
Recommendations		9	
• VHA	are	not	usually	helpful	 for	predicting	post-partum	haemorrhage	when	taken	10	
during	labour	in	a	non-bleeding	pregnant	woman.	Grade	2C.		11	
• VHA	 may	 be	 used	 as	 part	 of	 an	 agreed	 algorithm	 to	 manage	 postpartum	12	
haemorrhage	when	the	local	institution’s	major	obstetric	haemorrhage	protocol	is	13	
activated.	Grade	2C.	14	
• During	 ongoing	 major	 postpartum	 haemorrhage,	 if	 the	 FIBTEM	 A5	 is	 >12	 mm	15	
fibrinogen	replacement	is	unlikely	to	improve	clinical	haemostasis.	Grade	2B.		16	
• During	major	postpartum	haemorrhage,	 if	 FIBTEM	A5	 is	<7	mm,	or	<12	mm	with	17	
ongoing	bleeding,	fibrinogen	replacement	may	improve	clinical	haemostasis.	Grade	18	
2C.		19	
• In	 a	 bleeding	 pregnant	 or	 post-partum	 patient	 tranexamic	 acid	 should	 not	 be	20	
withheld	based	on	the	TEG	or	ROTEM	parameters.	Grade	1B.		21	
	22	
Liver	disease	and	Liver	Surgery		23	
Prediction	of	bleeding/coagulopathy		24	
13	
	
In	liver	disease,	VHA	have	a	better	predictive	value	for	bleeding	(Fayed	et	al,	2015,	Tafur	et	1	
al,	 2016,	 Pustavoitau	 et	 al,	 2017)	 and	 re-bleeding	 than	 SLTs	 (Chau	 et	 al,	 1998).	 A	2	
retrospective,	single	centre	study	comparing	SLT	and	ROTEM	in	post-operative	bleeding	 in	3	
adult	 liver	 transplant	 (LT)	 patients	 found	 several	 ROTEM	 parameters	 predicted	 bleeding	4	
(cut-offs	shown	in	brackets):	EXTEM	CT	(≥65	secs),	INTEM	CFT	(≥181	secs),	FIBTEM	A10	(≤13	5	
mm)	and	FIBTEM	MCF	(≤15	mm)	(area	under	the	curve	(AUC)	0.682,	0.615,	0.615	&	0.611	6	
respectively)	 compared	 to	 no	 SLT	 tests	 (Dotsch	 et	 al,	 2017).	 In	 cirrhotic	 patients,	 ROTEM	7	
values	 were	 associated	 with	 bleeding,	 specifically,	 reduced	 EXTEM	 MCF	 (median	 values	8	
bleeding	vs	non-bleeding:	38	mm	vs	43	mm)	and	FIBTEM	MCF	(8mm	vs	13	mm),	and	these	9	
values	were	associated	with	lower	factor	XIII	levels	(Bedrelli	et	al,	2016).	10	
	11	
A	prospective	observational	study	 in	263	LT	patients	with	transfusion	thresholds	based	on	12	
SLTs,	 found	 the	 best	 threshold	 that	 predicted	 platelet	 transfusion	 was	 A10	 (EXTEM)	 ≤35	13	
mm,	 and	 for	 fibrinogen	 an	 A10	 (FIBTEM)	 ≤	 8	 mm	 (Blasi	 et	 al,	 2012),	 with	 a	 negative	14	
predictive	value	(NPV)	95%	and	positive	predictive	value	(PPV)	27%.	A	retrospective	analysis	15	
of	ROTEM	datasets	in	239	LT	patients	concluded	that	the	EXTEM	and	FIBTEM	A5	measures	16	
can	 be	 used	 to	 guide	 therapy	 (Song	 et	 al	 2014)	 with	 an	 EXTEM	 A5	 <27	 mm	 predicting	17	
platelet	 count	 <50	 x10
-9
	 per	 litre	 and	 FIBTEM	A5	 <	 5	mm	predicting	 fibrinogen	 <	 1.0	 g/l.	18	
Patients	with	values	above	these	ranges	were	unlikely	to	bleed.	19	
	20	
Diagnosis	of	bleeding/coagulopathy		21	
SLTs	frequently	indicate	a	hypocoagulable	state	in	patients	with	liver	disease,	whereas	VHAs	22	
exhibit	a	spectrum	from	hypo-	to	hypercoagulable.	In	a	cohort	of	273	patients	with	cirrhosis,	23	
TEG	parameters	were	within	normal	limits,	although	the	MA	decreased	in	proportion	to	the	24	
14	
	
severity	 of	 liver	 disease	 and	 degree	 of	 thrombocytopenia	 (Stravitz	 et	 al,	 2012).	 A	 good	1	
correlation	 has	 been	 reported	between	 the	MCF	 and	platelet	 count	 and	 fibrinogen	 levels	2	
(Roullet	et	al,	2010).	But,	although	TEG	ff	and	FIBTEM	correlate	well	with	Clauss	fibrinogen,	3	
they	can	overestimate	 low	 levels	 (<1.0	g/l)	especially	at	 the	time	of	graft	reperfusion,	and	4	
should	be	interpreted	with	caution	(Yang	et	al,	2014).	5	
	6	
Hyperfibrinolysis	 is	 a	 significant	 cause	 of	 non-surgical	 bleeding	 in	 LT,	 with	 the	 highest	7	
incidence	occurring	 immediately	after	graft	reperfusion.	A	prospective	observational	study	8	
in	 37	 LT	 comparing	 ROTEM	and	 TEG	 (Abuelkasem	et	 al,	 2016)	 showed	 that	 tissue	 factor-9	
triggered	ROTEM	tests	were	more	sensitive	than	contact-activated	kaolin	TEG	in	identifying	10	
hyperfibrinolysis.	 (This	 study	 is	 limited	 by	 using	 VHA	manufacturers’	 definitions	 for	 lysis,	11	
without	 an	 additional	 gold	 standard	 measure	 (ML>15%	 ROTEM;	 Lysis30>8%	 TEG)).	 A	12	
heparin-like	 effect	 (HLE)	 due	 to	 release	 of	 endogenous	 heparinoids	 at	 the	 time	 of	 graft	13	
reperfusion	 is	 commonly	 seen	 on	 VHA	 (Pivalizza	 et	 al,	 1998)	 but	 whether	 this	 transient	14	
effect	 contributes	 to	 bleeding	 is	 controversial.	 It	 is	 recommended	 that	 TEG	 heparinase	15	
assays	or	HEPTEM	are	run	immediately	after	graft	reperfusion	(Agarwal	et	al,	2008).		16	
	17	
Use	of	ROTEM/TEG	for	guiding	transfusion	and	haemostatic	therapy	18	
The	perceived	utility	of	TEG	and	ROTEM	for	intra-operative	haemostatic	monitoring	has	led	19	
to	VHAs	becoming	a	standard	of	care	in	many	LT	units,	despite	the	lack	of	high	quality	data.	20	
The	 European	 Society	 of	 Anaesthesiologists	 guidelines	 recommend	 VHA	 use	 during	 LT	21	
(grade1C)	(Kozek-Langenecker	et	al,	2017).		From	a	practical	stance,	the	major	benefit	is	for	22	
patients	with	a	high	risk	of	bleeding	 (Model	 for	End	Stage	Liver	Disease	score	 (MELD)	>21	23	
and	/or	expected	difficult	surgical	dissection)	and	those	poly-transfused	intra-operatively.	In	24	
15	
	
this	 setting	 ROTEM	 has	 been	 shown	 to	 significantly	 reduce	 blood	 component	 use	 (p	 =	 <	1	
0.05)	and	to	reduce	post-operative	complications	(Alamo	et	al,	2013).	2	
	3	
Other	observational	studies	have	shown	VHA-based	algorithms	reduce	transfusion	during	LT	4	
(Kang	 et	 al,	 1985;	 Trzebicki	 et	 al,	 2010)	 and	 increase	 numbers	 of	 patients	 free	 from	5	
transfusions.	One	study	showed	a	rise	of	non-transfused	patients	from	5	to	24%	(p	<0.001),	6	
with	concomitant	reduction	of	massive	transfusion	from	13	to	2%	(p	<0.005)	(Leon-Justel	et	7	
al,	 2015).	 To	 date,	 the	 only	 RCT	 (n	 =	 28)	 of	 TEG	 versus	 SLT	 demonstrated	 a	 significant	8	
reduction	 in	 FFP	 administration	 in	 the	 TEG	 group	with	 a	 trend	 to	 less	 transfusion	 overall	9	
(Wang	 et	 al,	 2010).	 A	 Cochrane	 review	 (Gurusamy	 et	 al,	 2011)	 concluded	 that	 VHA	may	10	
decrease	blood	loss	and	transfusion	requirements	in	LT.		11	
	12	
There	 are	 a	 number	 of	 treatment	 algorithms	 developed	 by	 different	 LT	 centres.	 The	13	
consensus	 in	 the	 liver	 transplant	 community	 is	 not	 to	 correct	 VHA	 abnormalities	 unless	14	
there	 is	active	bleeding.	The	cut	off	values	that	would	trigger	pre-emptive	treatment	have	15	
not	been	established	and	may	lie	significantly	outside	normal	ranges	(i.e.	>15%)	(Wang	et	al,	16	
2012).		17	
		18	
The	 clot	 strength	 is	 a	 composite	 measure	 of	 fibrinogen-platelet	 interaction,	 and	 VHA	19	
monitoring	without	assessment	of	fibrinogen	can	lead	to	increased	transfusion	of	platelets	20	
(Larsen	et	 al,	 2011)	with	 potentially	 detrimental	 effects	 (de	 Boer	et	 al,	 2008).	 Algorithms	21	
that	 include	 TEG	 ff	 or	 FIBTEM	 cut	 offs	 for	 fibrinogen	 administration	 in	 patients	 who	 are	22	
actively	 bleeding	 increases	 the	 use	 of	 fibrinogen	 replacement	 but	 significantly	 reduces	23	
overall	transfusion	(De	Pietri	et	al,	2016;	Noval-Padillo	et	al,	2010).	There	is	less	information	24	
16	
	
for	thresholds	to	guide	prothrombin	complex	concentrate	(PCC)	or	FFP,	but	a	retrospective	1	
review	of	266	LT	used	a	CT	(EXTEM)	≥	80	s	as	a	threshold	for	PCC	and	a	CT	INTEM	of	≥	240	s	2	
for	 FFP	 transfusion	 (Kirchner	et	 al	 2014).	 This	 study	 showed	an	 increased	use	of	RBC	and	3	
platelets	in	the	patients	receiving	PCC,	however,	this	group	had	a	significantly	higher	MELD	4	
score	(p<0.0001)	than	the	group	that	did	not	receive	coagulation	factor	concentrates.	5	
	6	
Recommendations:	7	
• PT/INR	does	not	reliably	predict	bleeding	risk	in	patients	with	liver	disease.	Grade	8	
1B.	9	
• Heparinase	tests	are	recommended	at	graft	reperfusion	to	determine	the	extent	of	10	
any	HLE.	Grade	2B.	11	
• In	 bleeding	 patients,	 VHA	 (FIBTEM,	 TEG	 ff)	 should	 be	 used	 to	 guide	 fibrinogen	12	
replacement.	Grade	1C.	13	
• VHA	 can	 be	 used	 in	 liver	 transplant	 patients	 to	 reduce	 overall	 transfusion	14	
requirement	 (a	 normal	 VHA	 trace	 has	 a	 95%	 NPV	 for	 transfusion	 requirement).	15	
Grade	1C.	16	
	17	
Cardiac	surgery		18	
The	 use	 of	 VHA	 has	 been	 studied	 in	 the	 setting	 of	 cardiac	 surgery.	 One	 publication	19	
compared	all	three	VHAs	in	a	prospective	observational	study	of	35	patients,	using	them	at	20	
1	 hr	 and	 24	 hrs	 post-operatively	 compared	 with	 SLTs,	 and	 found	 TEG	 to	 be	 the	 most	21	
sensitive	 in	 detecting	 abnormal	 platelet	 counts,	 prolonged	 aPTT	 and	 reduced	 fibrinogen	22	
(Espinosa	et	al,	2014).	Sonoclot	was	the	 least	sensitive,	although	none	of	the	patients	had	23	
17	
	
markedly	 abnormal	 haemostasis	 and	 clinical	 outcomes	were	not	 assessed	 (Espinosa	et	 al,	1	
2014).		2	
	3	
Prediction	and	diagnosis	of	bleeding/coagulopathy		4	
The	majority	 of	 studies	 looking	 at	 prediction	 of	 bleeding	 have	 been	 small	 and	 have	 used	5	
variable	 definitions	 of	 major	 bleeding,	 which	 makes	 comparison	 of	 studies	 difficult.	6	
Preoperative	 (pre-bypass)	 VHA	 testing	 as	 an	 isolated	 test	 has	 not	 been	 shown	 to	 predict	7	
bleeding.	 Post-bypass	 VHA	 testing	 is	 moderately	 predictive	 of	 bleeding,	 however	 most	8	
studies	have	shown	that	the	values	obtained	are	often	still	in	the	normal	range,	and	that	the	9	
difference	 between	 the	 pre-	 and	 post-bypass	 tests,	 rather	 than	 the	 absolute	 values	10	
obtained,	 predicts	 bleeding.	 A	 change	 in	 any	 of	 the	 VHA	 variables	 >15%	 is	 most	 often	11	
associated	with	increased	risk	of	bleeding.		12	
	13	
Use	of	ROTEM/TEG/Sonoclot	for	guiding	transfusion	and	haemostatic	therapy	14	
VHA-directed	management	 has	 been	 reported	 to	 improve	 overall	 clinical	 outcomes	 after	15	
cardiac	surgery	 (Pearse	et	al,	2015	Sartorius	et	al,	2014	Trevisan	et	al,	2016,	Weber	et	al,	16	
2012),	 and	 result	 in	 less	bleeding	and	 lower	need	 for	 re-exploration	after	 coronary	artery	17	
bypass	 grafting	 (CABG)	 (Speiss	 et	 al,	 1995).	 Duration	 of	 hospitalisation	 was	 also	 reduced	18	
(Ichikawa	 et	 al,	 2017).	 Conversely,	 a	 recent	 systematic	 review	 of	 15	 randomised	 trials	19	
involving	 8737	 patients	 found	 no	 significant	 difference	 in	 mortality,	 reoperation	 or	20	
postoperative	 recovery	 (Serraino	 &	 Murphy,	 2017),	 with	 benefits	 being	 the	 reduction	 in	21	
transfusion	requirements	only.	However,	when	used	in	combination	with	other	techniques,	22	
such	as	a	smaller	bypass	circuit	(Mehaffey	et	al,	2017),	or	a	general	package	of	intervention	23	
(Ranucci	et	al,	2017)	clinical	outcomes	have	been	significantly	improved.	24	
18	
	
	1	
A	TEG-guided	approach	can	reduce	use	of	allogeneic	components	by	up	to	58%,	compared	2	
to	SLTs	(Westbrook	et	al,	2009).	 	 	Similarly,	30-80%	reduction	in	blood	component	use	has	3	
been	demonstrated	with	 intraoperative	ROTEM	(Karkouti	et	al,	2015;	Royston	et	al,	2001;	4	
Romlin	et	al,	2013,	Ichikawa	et	al,	2017),	and	in	the	setting	of	hypothermic	cardiac	arrest	for	5	
proximal	cardiac	surgery	(Fassl	et	al,	2013,	Girdauskas	et	al,	2010).	6	
	7	
Ak	et	al,	2009	showed	that	using	the	TEG	parameters	R	time	and	MA	to	guide	management	8	
led	to	a	significant	reduction	in	platelet	and	FFP	use	(n	=	110)	when	compared	to	clinician-9	
directed	transfusion	without	TEG	(n	=	114)(Ak	et	al,	2009).	These	results	were	replicated	in	a	10	
second	study	(Aoki	et	al,	2012).	Systematic	reviews	of	nine	(Fahrendorff	et	al,	2017)	and	15	11	
(Serraino	&	Murphy,	2017)	studies	where	patients	have	been	randomised	to	VHA-directed	12	
management	or	empirical	management,	have	given	differing	results	with	respect	to	volume	13	
of	platelet	 transfusions.	However,	 the	new	generation	VHAs	 incorporate	platelet	 function	14	
testing	and	when	 specific	 cut-off	 values	of	preoperative	platelet	 function	 tests	have	been	15	
used	 to	 direct	 timing	 of	 surgery	 this	 has	 resulted	 in	 a	 significant	 reduction	 in	 surgical	 re-16	
exploration	rate,	use	of	FFP,	and	use	of	platelet	concentrates	(Ranucci	et	al,	2017).	17	
	18	
In	 paediatric	 cardiac	 surgery,	 TEG-guided	 management	 has	 resulted	 in	 more	 effective	19	
cessation	of	postoperative	bleeding	compared	to	SLT	guided	therapy	(Niebler	et	al,	2012).	20	
Randomised	 trials	 have	 shown	 the	 same	 effect	 following	 ROTEM-directed	 therapy	 with	21	
significant	 reductions	 in	 postoperative	 bleeding	 and	 blood	 component	 requirements	22	
(Nakayama	et	al,	2015;	Romlin	et	al,	2013).	Analysis	of	ROC	curves	of	ROTEM	parameters	in	23	
19	
	
150	children,	showed	EXTEM	CT>111	s,	EXTEM	A10	<38	mm	and	FIBTEM	A10	<3	mm	could	1	
be	used	to	guide	management	(Faraoni	et	al,	2015).	2	
	3	
Studies	have	also	 found	good	correlation	between	FIBTEM	and	Clauss	 fibrinogen	 in	adults	4	
(Mace	et	al,	2016;	Ogawa	et	al,	2012)	and	children	(Pekelharan	et	al,	2014)	and	decreasing	5	
levels	 of	 fibrinogen	 can	 be	 quickly	 determined	 (Romlin	et	 al,	 2013).	 Ortmann	 et	 al,	 2015	6	
showed	superiority	of	FIBTEM	over	Clauss	fibrinogen.	VHA	can	be	used	as	a	valid	assessment	7	
of	 fibrinogen	 concentration	 to	 guide	 fibrinogen	 replacement	 leading	 in	 some	 cases	 to	8	
complete	avoidance	of	FFP	and	platelets	(Rahe-Meyer	et	al,	2009).	9	
	10	
In	 general,	 reduction	 in	 blood	 component	 use	 may	 be	 equal	 when	 guided	 by	 VHA	 or	11	
laboratory-derived	 algorithms	 but	 both	 appear	 to	 be	 better	 than	 clinician	 directed	12	
transfusion	(Avidan	et	al,	2014)	and	the	delays	in	waiting	for	SLTs	support	the	need	for	VHAs	13	
in	the	management	of	these	patients.	14	
	15	
Recommendations:	16	
• Pre-operative	VHA	has	not	been	shown	to	be	useful	for	predicting	bleeding	in	patients	17	
having	cardiac	surgery.	Grade	2B.	18	
• Patients	with	 a	 normal	 or	 abnormal	 postoperative	VHA	 and	 no	 bleeding	 should	 not	19	
receive	empirical	blood	components.	Grade	2A.	20	
• Superiority	 over	 laboratory	 tests	 in	 predicting	 bleeding	 has	 not	 been	 consistently	21	
demonstrated.	Grade	2C.	22	
• A	 single	 post-operative	 VHA	 test	 may	 not	 be	 useful	 for	 prediction	 of	 bleeding.	23	
However,	 if	 deterioration	 of	 VHA	 parameters	 is	 seen	 on	 repeat	 testing,	 the	 patient	24	
20	
	
should	 be	 closely	 monitored	 for	 bleeding	 and	 intervention	 with	 appropriate	 blood	1	
components	should	be	considered.	Grade	2B.	2	
• Cardiac	 surgery	 services	 should	 use	 transfusion	 protocols	 based	 on	 VHA	 testing	 to	3	
reduce	use	of	blood	components	and	potentially	improve	clinical	outcomes	in	bleeding	4	
patients.	Grade	2B.	5	
• VHA	can	be	used	as	a	valid	assessment	of	fibrinogen	concentration	to	guide	fibrinogen	6	
replacement.	Grade	1B.	7	
	8	
Trauma		9	
Prediction	of	bleeding	and	coagulopathy		10	
Many	 observational	 studies	 have	 explored	 whether	 VHA	 can	 reliably	 predict	 bleeding.	11	
Sixteen	 studies	 gave	 a	 threshold	 VHA	 parameter	 that	 could	 be	 used	 as	 a	 cut-off	12	
above/below	which	transfusion	was	more	likely	to	be	given,	but	very	few	gave	data	on	the	13	
sensitivity/specificity	 of	 their	 reported	 VHA	 threshold.	 Broadly,	 the	 majority	 of	 the	14	
thresholds	that	predicted	transfusion	represented	measurements	of	clot	strength.	Only	one	15	
of	these	thresholds	(EXTEM	A5	35	mm,	below	which	a	patient	is	deemed	to	be	at	high	risk	of	16	
bleeding)	has	been	externally	validated	(Davenport	et	al,	2011a	-	validated	by	Hagemo	et	al,	17	
2015),	 limiting	the	validity	of	the	other	results	to	centres	outside	the	reporting	institution.	18	
Davenport	demonstrated	that	EXTEM	A5	of	35	mm	or	more	had	a	high	NPV	for	transfusion	19	
need.	The	 finding	of	VHA-detected	 fibrinolysis,	 commonly	 reported	with	TEG	as	>3%	 lysis,	20	
has	 also	 consistently	 been	 associated	 with	 patients	 who	 have	 required	 large	 transfusion	21	
volumes,	however	VHA	are	insensitive	to	mild/moderate	fibrinolysis	and	should	not	be	used	22	
to	withhold	TXA	(Raza	et	al,	2013).	Several	systematic	reviews	have	highlighted	the	limited	23	
21	
	
nature	of	the	available	evidence	(Da	Luz	et	al,	2014;	Whiting	et	al,	2015;	Hass	et	al,	2014,	1	
Hunt	et	al,	2014).	2	
	3	
Diagnosis	of	traumatic	coagulopathy/bleeding	4	
VHA	 tests	 have	 been	 used	 in	 a	 variety	 of	 ways	 to	 diagnose	 traumatic	 coagulopathy.	 A	5	
common	method	has	been	to	explore	the	relationship	between	VHA	and	SLTs.	Many	studies	6	
report	 good	 correlations,	 with	 the	 majority	 defining	 coagulopathy	 using	 a	 PT-based	7	
measure.	More	trauma	patients	are	found	to	have	clotting	abnormalities	using	ROTEM	than	8	
using	SLTs	(64%	vs.	10.5%)(Doran	et	al,	2010).	No	comparative	data	are	available	for	TEG.		9	
	10	
VHA	measures	which	 are	used	 to	diagnose	 trauma	 coagulopathy	 vary	 but	 can	be	broadly	11	
summarised	 by	 three	 main	 changes:	 prolongation	 of	 clot	 formation;	 reduction	 in	 clot	12	
strength	and	increase	in	fibrinolysis.	The	most	common	abnormalities	include:	reduction	in	13	
A	 and	 MCF	 (ROTEM)	 (Wooley	 et	 al,	 2013,	 Meyer	 et	 al,	 2014,	 Tauber	 et	 al,	 2011)	 and	14	
reduction	in	MA	(TEG)	(Meyer	et	al,	2014,	White	et	al,	2015)	–	all	measures	of	clot	strength,	15	
and	 low	 clot	 strength	 is	 viewed	 as	 an	 important	 marker	 suggesting	 higher	 bleeding	 risk.	16	
However,	 no	 consensus	 value	 is	 yet	 agreed	–	 for	 example	Davenport	et	 al,	 2011	used	 an	17	
EXTEM	A5	of	≤35	mm	as	diagnostic	of	 trauma	coagulopathy	whereas	Hagemo	et	al,	 2015	18	
used	 ≤40	 mm.	 Other	 reported	 VHA	 changes	 include	 prolongation	 of	 CT	 and	 CFT	 and	19	
reduction	of	alpha	angle	(ROTEM)	(Tauber	et	al,	2011),	prolonged	R	times	(TEG)	(Meyer	et	20	
al,	2014)	and	increased	LY30	(rTEG)	(Moore	et	al,	2017).		21	
	22	
VHA	for	guiding	transfusion	and	haemostatic	therapy	23	
22	
	
VHA	guided	transfusion	algorithms	for	management	of	severe	trauma	bleeding	have	been	1	
widely	 reported	 using	 TEG	 and	 ROTEM.	 TEG	 algorithms	 vary	 according	 to	 institution,	2	
although	the	general	principles	were	similar	across	all	studies.	There	were	far	fewer	ROTEM	3	
data	 available	 and	 most	 studies	 arise	 from	 the	 same	 institution	 (Innerhofer	 et	 al,	 2017,	4	
Schochl	 et	 al,	 2010	 and	 2011).	 These	 studies	 provide	 ROTEM	 values	 for	 transfusion	 of	5	
fibrinogen	concentrate	and	PCC,	with	no	clear	guide	for	platelet	transfusion	and	no	mention	6	
of	fibrinolysis.	7	
	8	
The	observational	studies	provide	low	quality	data	suggesting	that	VHA-guided	transfusion	9	
algorithms	(mostly	TEG)	reduce	mortality	(Johansson	et	al,	2009;	Kashuk	et	al,	2012;	Schochl	10	
et	 al,	 2010;	 Tapia	 et	 al,	 2013);	 change	 transfusion	 practices	 when	 compared	 to	 empiric	11	
therapy	 (Mamczak	et	al,	 2016,	 Tapia	et	al,	 2013)	 and	 reduce/avoid	 allogeneic	 transfusion	12	
(Schochl	et	al,	2011a,	Yin	et	al,	2014).	Data	 from	a	pre-	and	post-implementation	military	13	
study	 demonstrated	 increased	 use	 of	 blood	 components	 (platelets	 four	 fold	 and	14	
cryoprecipitate	two	fold)	after	incorporating	ROTEM	into	resuscitation	practices	(Prat	et	al,	15	
2017)	despite	similar	patient	characteristics	and	rates	of	coagulopathy.	This	study	suggests	16	
that	non	VHA-based	 transfusion	may	underestimate	 the	need	 for	platelets	and	 fibrinogen	17	
supplementation.	18	
	19	
One	RCT	using	rapid-TEG	(Gonzalez	et	al,	2016)	reported	a	significant	reduction	in	death	at	20	
28	 d	with	 VHA:	 20	 deaths	 SLT	 (36.4%)	 vs.	 11	 VHA	 (19.6%).	Median	 times	 to	 death	were	21	
shorter	in	the	VHA	arm	(4.2	h	vs.	10.4	h)	and	numbers	of	haemorrhagic	deaths	lower	(8.9%	22	
vs.	 20%).	 This	 study	provides	 evidence	 that	VHA-guided	 transfusion	may	be	beneficial	 for	23	
the	management	of	acute	bleeding	 in	trauma,	over	and	above	the	effects	of	empiric	1:1:1	24	
23	
	
transfusion.	However,	the	study’s	limitations	must	be	highlighted:	it	was	single	centre;	large	1	
volumes	of	crystalloids	were	used	in	resuscitation;	participants	were	allocated	to	study	arms	2	
according	to	the	week	of	the	year,	and	after	two-thirds	of	the	participants	were	enrolled	the	3	
VHA	algorithm	was	changed.	It	is	impossible	to	say	what	effect	this	would	have	on	outcome	4	
but	raises	questions	about	the	overall	validity	of	the	study.	5	
	6	
A	 second	 single-centre	 RCT	 used	 ROTEM	 guided	 thresholds	 to	 compare	 FFP	 with	 factor	7	
concentrates	(fibrinogen	concentrate	(FgC)	and	PCC)	(Innerhofer	et	al,	2017).	The	trial	used	8	
dual	ROTEM	measures	(FIBTEM	A10	>8	mm,	EXTEM	CT	<78	s)	in	combination	with	a	clinical	9	
measure	 of	 bleeding	 to	 define	 achievement	 of	 haemostasis	with	 the	 primary	 endpoint	 of	10	
multiple	 organ	 failure.	 As	 a	 result	 of	 high	 treatment	 failure	 in	 the	 FFP	 arm	 (inability	 to	11	
correct	 coagulopathy	 and	 need	 for	 rescue	 therapy	 with	 PCC)	 the	 study	 was	 terminated	12	
early.		The	authors	reported	an	association	between	clinically	relevant	bleeding	and	ROTEM	13	
measurements	 that	 could	 be	 used	 as	 a	 threshold	 to	 withhold	 transfusion.	 A	 large	multi-14	
centre	 RCT	 (iTACTIC)	 evaluating	 VHA-	 and	 SLT-based	 transfusion	 algorithms	 in	 trauma	15	
haemorrhage	is	due	to	be	completed	in	2018	and	results	are	awaited	(NCT02593877).		16	
	17	
Recommendations:		18	
•	 Normal	VHA	 results	 confer	a	high	negative	predictive	value	 for	 transfusion	need,	19	
enabling	 the	 clinical	 team	 to	 monitor	 the	 patient	 closely	 without	 immediate	20	
activation	of	the	major	haemorrhage	protocol.	Grade	2B.	21	
• Low	clot	strength	measures	on	TEG	and	ROTEM	and	lysis	of	greater	than	3%	on	TEG	22	
may	be	used	as	an	indicator	that	a	trauma	patient	is	at	higher	risk	of	requiring	RBC	23	
and	blood	components.	Grade	2C.	24	
24	
	
• VHA,	particularly	TEG,	may	reduce	mortality	and	reduce	transfusion	exposure	and	1	
if	 available	may	 be	 considered	 for	 transfusion	 guidance	 in	 trauma	haemorrhage.	2	
Grade	2B.	3	
• Tranexamic	acid	should	not	be	withheld	based	on	the	TEG	or	ROTEM	parameters.	4	
Grade	1B.		5	
	6	
Practical	use	of	VHA	devices.	7	
The	 published	 literature	 focuses	 on	 the	 use	 of	 VHAs	 to	 enable	 early	 identification	 of	8	
coagulopathy	and	to	guide	transfusion	of	blood	components.	From	a	practical	point	of	view	9	
it	 is	 important	 to	 repeat	 VHA	 tests	 after	 transfusion	 to	 assess	 the	 effect	 of	 haemostatic	10	
treatment	 interventions	 and	 to	 determine	 that	 there	 is	 no	 further	 deterioration	 in	 the	11	
haemostatic	profile	in	the	context	of	ongoing	bleeding.	However,	in	the	clinical	setting,	the	12	
confirmation	of	normal	coagulation	 is	one	of	 the	most	valuable	aspects	of	VHAs.	Not	only	13	
does	 this	 reduce	 unnecessary	 transfusion	 of	 blood	 components	 but	 it	 also	 directs	 clinical	14	
management	to	address	the	underlying	cause	of	haemorrhage.	This	effect	is	not	possible	to	15	
quantify	but	is	reinforced	by	clinicians	practicing	in	units	with	access	to	VHAs.		16	
	17	
General	practice	points	for	managing	major	haemorrhage	using	VHA:	18	
• Transfusion	algorithms	should	be	adapted	according	to	local	normal	ranges	and	19	
locally	validated.		20	
• Normal	VHA	parameters	are	a	useful	indicator	that	bleeding	due	to	coagulopathy	is	21	
unlikely	and	transfusion	of	blood	components	is	unlikely	to	be	needed.	22	
25	
	
• An	abnormal	VHA	result	is	relatively	poor	at	predicting	patients	who	will	bleed	and	1	
changes	in	serial	measurements	may	be	more	valuable.	2	
• When	 blood	 component	 transfusion	 is	 necessary,	 the	 use	 of	 VHA	 to	 guide	 and	3	
monitor	 replacement	 has	 generally	 been	 found	 to	 reduce	 the	 volumes	 required	4	
and	improve	other	measures	of	outcome.		5	
	6	
How	to	approach	a	VHA	trace	–	general	principles	for	guiding	transfusion	therapy	7	
There	 are	 no	 universally	 agreed	 algorithms	 however	 the	 general	 principles	 of	 how	 to	8	
approach	VHA-guided	transfusion	are	set	out	in	Table	2.			9	
	10	
Areas	for	future	research	11	
The	following	areas	for	future	research	are	suggested:	12	
• Define	measures	 for	achievement	of	haemostasis	 to	provide	a	 consensus	outcome	13	
for	clinical	study	reporting,	so	that	VHA	results	can	be	compared	across	studies	and	14	
across	patient	groups	15	
• Clinical	 studies	 to	 compare	 the	 efficacy	 and	 cost	 effectiveness	 of	 VHA-supported	16	
transfusion	algorithms	with	standard	care	during	obstetric	and	trauma	bleeding			17	
• Large	 multi-centre	 clinical	 trials	 evaluating	 TEG	 or	 ROTEM	 algorithms	 in	 major	18	
haemorrhage	 using	 standardised	 intervention	 points	 as	 well	 as	 standardised	19	
interventions,	allowing	comparison	between	studies	20	
• Future	studies	are	required	to	establish	if	improvement	in	the	VHA	profile	equates	to	21	
improvement	in	clinical	outcome.	22	
Conclusion	23	
26	
	
VHA	 devices	 have	 practical	 advantages	 as	 point	 of	 care	 devices	 for	 monitoring	 major	1	
haemorrhage	 including	 speed	 of	 results	 and	 a	 set	 of	 parameters	 that	 assesses	 a	 global	2	
coagulation	 profile.	 However,	 the	 lack	 of	 a	 systematic	 approach	 to	 their	 use,	 with	 low	3	
quality	published	data	that	has	not	been	clearly	linked	to	important	clinical	outcomes	means	4	
that,	at	present,	the	evidence	base	to	guide	practice	is	limited.		 	5	
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search	will	be	re-run	every	three	years	to	search	for	any	RCT	or	other	high	quality	data	that	3	
is	either	new	or	that	may	have	been	missed.	The	document	will	be	archived	and	removed	4	
from	the	BSH	current	guidelines	website	 if	 it	becomes	obsolete.	 If	new	recommendations	5	
are	 made	 an	 addendum	 will	 be	 published	 on	 the	 BSH	 guidelines	 website	 (www.b-s-6	
h.org.uk).		7	
	8	
Disclaimer	9	
While	the	advice	and	information	in	this	guidance	is	believed	to	be	true	and	accurate	at	the	10	
time	 of	 going	 to	 press,	 neither	 the	 authors,	 the	 BSH	 nor	 the	 publishers	 accept	 any	 legal	11	
responsibility	for	the	content	of	this	guidance.	12	
	13	
Supporting	Information	14	
Additional	supporting	information	may	be	found	in	the	online	version	of	this	article:	15	
Appendix	S1:	Search	narrative;	methodology	for	inclusion	of	studies	in	this	guideline	and	16	
the	PRISMA	flow	diagram	of	included	studies.	17	
18	
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Figure	1.	1	
	2	
	3	
a) Thromboelastography	 	 	 b)	Thromboelastometry	4	
	5	
			 																			 	6	
	7	
c) Sonoclot	8	
	9	
	10	
	11	
Whole	blood	is	placed	in	to	the	cup	for	each	device.	Activators	are	added,	as	required,	and	as	the	test	is	12	
started	a	pin	is	placed	in	to	the	middle	of	the	blood.	The	cup	or	the	pin	moves	relative	to	the	other	part	of	the	13	
machine	and	as	the	clot	forms	the	resistance	to	movement	that	is	built	up	by	fibrin	strands	coupling	the	pin	14	
and	cup	together	is	translated	by	a	variety	of	methods	into	a	graphical	trace.	A)	TEG:	the	cup	moves	through	a	15	
predefined	arc	(4°45’)	and	resistance	to	movement	is	detected	by	an	electromechanical	transducer	on	the	pin	16	
(Figure	provided	courtesy	of	Haemonetics).	B)	ROTEM:	differs	from	TEG	in	that	the	pin	oscillates	through	a	17	
known	arc	(4°75’)	and	detection	of	resistance	to	movement	is	picked	up	by	changes	to	light	transmission	which	18	
is	then	converted	into	a	TEM	trace	(TEMogram)	(Figure	provided	courtesy	of	Instrumentation	Laboratory).	C)	19	
Sonoclot:	The	plastic	pin,	which	is	mounted	on	to	an	ultrasonic	transducer,	vibrates	vertically	by	1	micrometre	20	
distances	at	200Hz	and	resistance	is	detected	by	an	electromechanical	transducer. 21	
	 	22	
30	
	
Table	1a.	TEG	reagents	1	
	 TEG	5000	
(cup	&	pin	method)	
TEG	6s	
(cartridge	method)	
What	the	trace	looks	at:	
Sample	type	 Fresh	WB	
Citrated	WB	
Citrated	WB	 -	
Tests	
available	
‘Plain	cup’:	
Kaolin	
CK:		
Kaolin,	Ca	
Standard	clot	formation	–	activating	the	
intrinsic	pathway	
	 ‘Heparinase	cup	‘	:	
Kaolin,	heparinase	
CKH:		
Kaolin,	heparinase,	Ca	
When	compared	to	a	standard	kaolin	
activated	trace	a	shorter	R	time	
suggests	the	presence	of	heparin	
	 rTEG:	
Kaolin,	TF	
CRT:	
Kaolin,	TF,	Ca	
Standard	clot	formation	activating	both	
intrinsic	and	extrinsic	pathways	
(particularly	helpful	for	major	
haemorrhage	and	rapid	results)	
	 FF:	
TF,	Reopro	
CFF:		
TF,	Reopro,	Ca	
Platelet	inhibitor	added:	contribution	of	
fibrinogen	to	clot	remains.	
When	trace	is	compared		to	a	standard	
kaolin	trace	the	platelet	contribution	
can	be	estimated	
The	words	in	italics	indicate	the	names	given	to	the	assays	by	the	manufacturer.	The	reagents	used	in	these	2	
assays	are	described	beneath	each	italicised	name.	3	
Key:	Ca	–	calcium	chloride;	FF	–	functional	fibrinogen;	Reopro	–	a	GPIIb/IIIa	inhibitor,	inhibiting	platelet	4	
activity;	rTEG	–	rapid	TEG;	R	time	=	reaction	time;	TF	–	tissue	factor;	WB	–	whole	blood	5	
	6	
Table	1b.	ROTEM	reagents	7	
	 Gamma	and	delta	
(cup	and	pin	method)	
Sigma	
(cartridge	method)	
	What	the	trace	looks	at:	
Sample	
type	
Citrated	WB	 Citrated	WB	 -	
Tests	
available	
INTEM:	
Ellagic	acid	
‘ROTEM	sigma	complete	
cartridge’:	
Includes:	FIBTEM,	EXTEM,	
INTEM	and	APTEM	channels		
INTEM:	Standard	clot	formation	
–	activating	the	intrinsic	
pathway	
	 EXTEM:		
TF	
‘ROTEM	sigma	complete	+hep	
cartridge’:	
Includes:	FIBTEM,	EXTEM,	
INTEM	and	HEPTEM	channels	
EXTEM:	Standard	clot	
formation	–	activating	the	
extrinsic	pathway	
	 HEPTEM:	
Ellagic	acid,	heparinase	
	 HEPTEM:	When	compared	to	
an	INTEM	trace	a	shorter	CT	
time	suggests	presence	of	
heparin	
	 FIBTEM:	
TF	+	cytochalasin	C		
	 FIBTEM:	Platelet	inhibitor	
added:	contribution	of	
fibrinogen	to	clot	remains.	
Can	compare	results	to	EXTEM	
trace	to	get	idea	of	platelet	
contribution	
	 APTEM:	
TF	+	aprotinin	
	 APTEM:	Aprotinin	added:	trace	
compared	to	EXTEM,	
differences	in	MA/MCF	suggest	
contribution	of	fibrinolysis	
The	words	in	italics	indicate	the	names	given	to	the	assays	by	the	manufacturer.	The	reagents	used	in	these	8	
assays	are	described	beneath	each	italicised	name.	9	
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Key:	CT	–	clotting	time;	MA	–	maximum	amplitude;	MCF	–	maximal	clot	formation;	TF	–	tissue	factor;	WB	–	1	
whole	blood	2	
	3	
	4	
Table	1c.	Sonoclot	reagents	5	
	 Sonoclot	 What	the	trace	looks	at:	
Sample	type	 Fresh	WB,	Citrated	WB,	
plasma	
	
Tests	available	 kACT:	
Kaolin	
Used	to	manage	heparin	therapy	(with/without	aprotinin)	
	 Son	ACT:	
Celite	
Used	to	manage	heparin	therapy	(without	aprotinin)	
	 aiACT:	
Celite,	clay	
Used	to	manage	heparin	therapy,	with	aprotinin	
	 gbACT+:	
Glass	beads	
Standard	clotting	assessment	and	platelet	function	for	use	in	
non-heparinised	patients	
	 H-gbACT+:	
Glass	beads	+	heparinase	
Standard	clotting	assessment	and		platelet	function	for	use	in	
heparinised	patients	
The	words	in	italics	indicate	the	names	given	to	the	assays	by	the	manufacturer.	The	reagents	used	in	these	6	
assays	are	described	beneath	each	italicised	name.	7	
Key:	WB	–	whole	blood	8	
	9	
	 	10	
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Figure	2.	1	
	2	
TEG	and	ROTEM	traces.	3	
	4	
		5	
TEG	and	ROTEM	traces	can	be	broadly	divided	into	4	main	sections:	(a)	time	to	first	fibrin	formation	(reaction	®	6	
time	-	TEG5000;	activated	clotting	time	(ACT)	–	TEG6s;	clotting	time	(CT)	–	ROTEM);	(b)	kinetics	of	fibrin	7	
polymerisation	which	has	two	parameters	which	are	directly	interchangeable	(alpha	angle	used	by	both	8	
devices)	and	additionally	the	time	it	takes	from	first	fibrin	formation	to	when	arbitrarily	the	clot	is	20mm	wide	9	
(kinetics	(K	)time	–	TEG5000;	clot	formation	time	(CFT)	–	ROTEM);	(c)	measures	of	clot	strength	–	often	10	
demarcated	at	5	minute	intervals	(amplitude	(A)		-	A30	–	TEG	clot	strength	at	30	minutes;	clot	amplitude	(CA)	-	11	
CA30	–	ROTEM	clot	strength	at	30	minutes)	and	with	a	peak	measurement		(maximal	amplitude	(MA)	–	TEG;	12	
maximum	clot	formation	(MCF)	–	ROTEM);	(d)	measures	of	clot	breakdown/lysis,	usually	presented	as	a	13	
percentage	of	reduction	in	the	clot	strength	measure	compared	to	maximal	measurement	(Lysis	(Ly)	–	TEG;	14	
clot	lysis/lysis	index/maximal	lysis	(CL/LI	/ML)–	ROTEM).	15	
	16	
	 	17	
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Figure	3.		1	
Sonoclot	trace.	2	
	3	
	4	
	5	
	6	
The	Sonoclot	trace	is	shown	above	and	is	divided	into	4	distinct	sections:	(a)	Activated	clotting	time	(ACT)	–	the	7	
time	in	seconds	from	the	start	of	the	test	until	first	fibrin	is	formed;	(b)	Clot	rate	–	the	maximum	slope	during	8	
initial	clot	formation	as	shown	by	the	line	R1	above;	(c)	time	to	peak	–	the	time	in	seconds	which	provides	an	9	
indication	of	how	rapidly	fibrinogen	is	converted	to	fibrin	and	how	well	platelets	are	activated;	(d)	Clot	10	
retraction	–	this	shows	whether	platelets	are	working	normally	by	retracting	after	activation.	11	
	 	12	
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	1	
Figure	4.		2	
	3	
TEG6s	technology.	4	
	5	
 	6	
	7	
	8	
	9	
	10	
	11	
	12	
	13	
	14	
	15	
	16	
	17	
	18	
	19	
The	TEG6s	measures	resonance	frequency.	The	blood	sample	is	exposed	to	various	frequency	vibrations	and	20	
the	up	down	motion	of	the	surface	of	the	blood	meniscus	is	measured	by	LED	illumination.	As	the	clot	forms	21	
the	resonance	alters	in	a	reproducible	way	and	can	be	converted	into	the	TEGogram.	(Figure	provided	courtesy	22	
of	Haemonetics).	23	
	24	
	25	
	26	
27	
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Table	2.	1	
	2	
	3	
	4	
	 CLOT	INITIATION	 CLOT	STRENGTH	 CLOT	LYSIS	
Test	 result	
shows:	
Prolonged	R,	ACT	
or	CT	
Reduced	
MA/MCF,	
normal	
fibrinogen†		
Reduced	
MA/MCF,	low	
fibrinogen†	
LY-30	>8%	
Li30	>15%	
What	 does	 this	
mean?	
Low	clotting	factors	
and/or	low	
fibrinogen	level	
	
Warfarin	use	
Heparin	use	
DOAC	use	(not	
Apixaban)	
Low	platelets		 Low	fibrinogen	 VHA	detected	
fibrinolysis*	
Therapy	
recommended	
FFP		
(PCC	might	be	
considered)	
Platelets		
	
Cryoprecipitate	or	
fibrinogen	
concentrate	
Consider	additional	
anti-fibrinolytic*	
Therapy	groups	 	 	 	 	
Obstetric	 FFP	if	R	or	CT	above	the	
normal	range.		
PCC	is	not	
recommended	
No	data	are	
available	to	guide	
platelet	transfusion	
Cryoprecipitate	or	
fibrinogen	
concentrate	if	
FIBTEM		<7	mm	or	
<12	mm	in	severe	
bleeding	
No	data	are	available	
for	guiding	
antifibrinolytic	therapy	
Liver	 FPP	if	results	above	
normal	range	
(PCC	might	be	
considered)	
EXTEM	MCF	<	35	
mm	
FIBTEM	<	7	mm	 Fibrinolysis	at	
reperfusion	may	correct	
spontaneously.		
Anti-fibrinolytics	are	
indicated	in	most	other	
circumstances.	
Cardiac	 FFP	if	>	15%	above	ULN	 Platelets	 Cryoprecipitate	or	
FgC	
	
Trauma	 FFP	if	results	at	upper	
end	or	above	normal	
range	
Give	platelets	if	
MA/MCF	at	lower	
end	or	below	the	
Cryoprecipitate	or	
FgC	if	FIBTEM	or	ff	
at	lower	end	or	
TEG	LY-30	≥3%	
indicates	clinically	
important	lysis		
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PCC	not	recommended	 normal	range	whilst	
ff	or	FIBTEM	normal	
below	the	normal	
range	
†	Clot	strength	measures	are	highly	dependent	on	platelets	and	fibrinogen.	To	differentiate	low	clot	strength	due	to	loss	of	1	
platelet	 function	or	 from	that	due	to	 low	fibrinogen	 levels,	 the	clot	strength	of	 the	 fibrinogen	assay	 (ff	–	TEG;	FIBTEM	–	2	
ROTEM)	should	be	compared	with	the	standard	TEG	or	ROTEM	EXTEM	trace,	respectively.	A	low	overall	clot	strength	with	a	3	
normal	 ff/FIBTEM	 would	 suggest	 lack	 of	 platelets	 contributing	 to	 the	 clot,	 whereas	 a	 low	 overall	 clot	 strength	 with	 a	4	
concomitant	low	ff/FIBTEM	would	point	to	lack	of	fibrinogen		5	
*Do	 not	 withhold	 an	 anti-fibrinolytic	 if	 is	 it	 clinically	 indicated	 and	 within	 3	 hours	 of	 injury	 or	 start	 of	 postpartum	6	
haemorrhage	7	
	8	
Key:	ACT	–	activated	clotting	time;	CT	–	clotting	time;	ff	–	functional	fibrinogen;	FFP	–	fresh	frozen	plasma;	FgC	–	fibrinogen	9	
concentrate;	 Li30	 –	 lysis	 at	 30	minutes;	 LY-30	 –	 lysis	 at	 30	minutes;	 	 MA	 –	maximal	 amplitude;	MCF	 –	maximum	 clot	10	
firmness;	 PCC	 –	 prothrombin	 complex	 concentrate;	 R	 –	 reaction	 time;	 ULN	 –	 upper	 limit	 of	 normal;	 VHA	 –	 viscoelastic	11	
haemostatic	assay	12	
	13	
	14	
	15	
